News & Events about Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical (NASDAQ:RARE Get Rating) was upgraded by equities research analysts at Guggenheim from a neutral rating to a buy rating in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm presently has a $50.00 price target on the biopharmaceutical ...
Globe Newswire
5 months ago
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (Ultragenyx), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases and ...
Ticker Report
5 months ago
Mirae Asset Global Investments Co. Ltd. trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) by 14.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The firm owned 136,906 shares of...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) Equities researchers at SVB Leerink issued their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Thursday, July 28th. SVB Leerink analyst J. Schwartz expects that the biopharmaceutical ...
Ticker Report
6 months ago
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE Get Rating) Investment analysts at Wedbush reduced their FY2026 earnings estimates for Ultragenyx Pharmaceutical in a research report issued to clients and investors on Friday, July 29th. Wedbush analyst L. Chico now expects that the ...